Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: Medivation is developing a drug called MDV3100 for the early treatment of advanced prostate cancer. Currently, there are limited options for treatment of this disease, with Dendreon's
Now what: MDV3100 is already in phase 3 testing for advanced prostrate cancer. The new trial announced today should determine whether it is effective earlier in the course of the disease, which would open up a larger market. Johnson & Johnson
Interested in more info on Medivation? Add it to your watchlist by clicking here.